Symbiotec Pharmalab Limited
Company at a glance · Human reviewed · 26 Aug 2026
The business, in brief
Symbiotec Pharmalab Limited is a research and development-driven, science-based pharmaceutical and biotechnology company with capabilities across three platforms: organic chemistry, biotechnology, and complex injectables. It holds a global leadership position in corticosteroid and steroidal-hormone APIs in volume terms.
- Customer concentration
- 57.59% top 10 customers
- Total borrowings
- ₹387.91 cr Fiscal 2026
- Corticosteroid APIs
- Steroidal-hormone APIs
- Complex injectables
- CDMO services
* Estimated date based on the standard exchange timeline. Unmarked dates are exchange-reported.
Calculated at the upper band of ₹988.00 per share. Amounts exclude blocked-funds variation.
Application field guide
Shares reserved for you
Estimate is possible allottees divided by applications. Where the exchange omits application counts, the floor assumes every bid used that category's minimum bid size. Final odds depend on valid applications and the basis of allotment.
Prospectus dossier
Numbers, plans & pressure points
A focused reading of the company's reported financials, planned use of proceeds, business strengths and material risks.
A multi-year view
Figures retain the units reported in the RHP| Fiscal year | Revenue | Profit after tax | Operating cash flow | Borrowings | Net worth |
|---|---|---|---|---|---|
| 2026 | ₹869.15 cr | ₹109.9 cr | ₹174.59 cr | ₹387.91 cr | ₹1,149.59 cr |
| 2025 | ₹751.55 cr | ₹96.79 cr | ₹47.26 cr | ₹540.92 cr | ₹814.71 cr |
| 2024 | ₹716.25 cr | ₹100.06 cr | ₹187.5 cr | ₹247.21 cr | ₹714.84 cr |
01 Use of funds
Where the
money goes.
02stated objects
in the filing
Prepayment and/or repayment, in full or in part, of all or a portion of certain outstanding borrowings availed by our CompanyRHP p. 138
General corporate purposes.RHP p. 138
02 Growth case
What could drive
the business.
05signals found
in the filing
Global leadership in corticosteroid and steroidal hormone APIs with a global volume market share of 38.2% in corticosteroid and 23.8% in steroidal-hormone APIs as of Fiscal 2026.RHP p. 146
Long-standing relationships with domestic and global customer base, serving over 200 customers across more than 40 countries as of March 31, 2026.RHP p. 146
Fully-invested, multi-scale, vertically integrated manufacturing platform with sustainable practices and clean regulatory track record.RHP p. 147
Increasing global demand for complex molecules and biotech-enabled small molecules, driving adoption of fermentation and specialized manufacturing.RHP p. 189
Strategic shift in global supply chains away from China (China+1 strategy) positioning India as a competitive alternative for manufacturing and sourcing.RHP p. 189
03 Risk factors
Read the downside first.
Selected material risks disclosed in the RHP. Read these before the upside case. This summary is not a substitute for the prospectus.
High Revenue Concentration from Sale of APIs and Top Products
We derive almost all of our revenue from the sale of APIs, which collectively constituted 96.07%, 99.10% and 100.00% of our revenue from operations in Fiscals 2026, 2025 and 2024, respectively. Further, our top five APIs constituted 62.27%, 63.16% and 60.37% of our revenue from operations in Fiscals 2026, 2025 and 2024, respectively.
Dependence on Manufacturing Facilities Located Entirely in Madhya Pradesh
Our manufacturing facilities and dedicated R&D centres are located in the state of Madhya Pradesh in India. Any adverse developments affecting Madhya Pradesh or its surrounding regions could adversely affect our business, results of operations, financial condition and cash flows.
Dependence on Key Customers
We derive a substantial portion of our revenue from certain key customers. Revenue generated from our top ten customers accounted for 57.59%, 55.90% and 61.65% of our revenue from sale of product in Fiscals 2026, 2025 and 2024, respectively.
Statutory Auditors Examination Report Modifications and Qualifications
Our statutory auditors examination report on the Restated Consolidated Summary Statements discloses certain modifications included in their report on the consolidated financial statements as at and for the years ended March 31, 2026, March 31, 2025 and March 31, 2024.
Significant Outstanding Legal Proceedings
Our Company and certain of our Directors and Subsidiaries are involved in certain legal proceedings. Any adverse decision in such proceedings may have an adverse effect on our business, results of operations, financial condition and cash flows.
Live issue demand
The book, in motion
Exchange timestamp 26 Aug 2026, 5:00 pm · checked 26 Aug 2026, 9:05 pm